Completed PHASE3 INTERVENTIONAL 2-arm NCT00004978

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT)

A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial

Sponsor: Chiron Corporation

Conditions HIV Infections

Interventions Recombinant interleukin-2 (rIL-2)

Updated 8 times since 2017 Last updated: Nov 2, 2021 Started: Mar 31, 2000 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Chiron Corporation and has accumulated 8 data snapshots since 2000. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiron Corporation
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Aarhus, Denmark , Adelaide, Australia , Amsterdam, Netherlands , Angers, France , Atlanta, United States , Bangkok, Thailand , Barcelona, Spain , Belfast, United Kingdom and 147 more locations